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Background: Sickle cell disease (SCD) is endemic in non-Western countries. Due to migration, the prevalence of
SCD in the Netherlands has increased. Adherence to medical treatment is recognized as a major problem area.
Therefore, new effective interventions to increase adherence are urgently needed.
Methods/design: The TEAM study is an ongoing randomized controlled trial (RCT) to compare protocolized
individual medical appointments (IMA’s; care-as-usual) with protocolized group medical appointments (GMA’s; novel
intervention) in pediatric (n = 40) and adult (n = 60) patients. The study aims to assess the effectiveness of GMA’s
(over a three year period) on patients’ self-efficacy, adherence, quality of life, morbidity, hospital admissions and
satisfaction with the treating professional; as well as to test the cost-effectiveness of GMA’s. In both the IMA and
GMA groups structured assessments will be performed at baseline (start of the study), after 1.5 and after 3 years.
Discussion: This is the first RCT to investigate the effectiveness of GMA’s on self-efficacy and adherence in pediatric
and adult patients with SCD, including a cost-effectiveness analysis.
Trial registration: NTR4750 (NL42182.000.12). Registered 13 August 2014.
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Cost-effectivenessBackground
Sickle cell disease and important aspects of care
Sickle cell disease (SCD) is an autosomal recessively inher-
ited red cell disorder caused by an abnormal production
of hemoglobin. It is characterized by severe chronic
anemia, fulminant infections due to functional asplenia,
and repetitive painful vaso-occlusive ischemic “sickle cell
crises”. The latter are often provoked by infection, fever,
pain, dehydration, cold and stress. Ultimately, multiorgan* Correspondence: m.cnossen@erasmusmc.nl
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bones, retinopathy, stroke, cardiomyopathy, pulmonary
hypertension and kidney failure, among others. Life ex-
pectancy is set at 45 years of age. Causes of death are
multifactorial but often due to organ failure caused by the
disease. Overall, the direct and indirect costs of SCD treat-
ment are substantial [1].
SCD is endemic in Africa, the countries bordering the
Mediterranean Sea (Morocco, Turkey), the Middle East
(Iran, Irak) and the Caribbean region (Surinam, Antilles,
Haiti and Dominican Republic). Moreover, carriership is
1:7 individuals from these regions. As more than 11 % of
the current Dutch population and more than 50 % of the
younger population in the larger cities originates fromticle is distributed under the terms of the Creative Commons Attribution 4.0
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was initiated by the Dutch government on January 1st
2007 [2], aiming to lower age at presentation and to im-
prove timely and adequate patient support. Since neonatal
screening was initiated, approximately 60 children with
SCD and 800 SCD carriers are born annually [3].
Therapeutic interventions for SCD include: infection
prevention by prophylactic antibiotics in the younger
population, vaccinations, folic acid supplemention, blood
transfusions in combination with iron chelation therapy,
hydroxycarbamide and antihypertension treatment. An
important part of treatment regimens consists of exten-
sive patient education on the importance of: antibiotic
prophylaxis, recognition of provoking risk factors for
painful sickle cell crises, early disease symptoms and
complications, lifestyle modifications as well as the in-
heritance of the disease.
Delivering adequate medical care for SCD patients is
often difficult due to the fact that most patients present
themselves when disease symptoms have already progressed
and exhibit poor adherence to medication and medical
visits, due to diverse patient related factors which are not
easily influenced [4, 5]. An important factor of treatment,
and by consequence prognosis, is “self-efficacy”. Self-efficacy
is defined as confidence in one’s own capabilities to manage
illness. Importantly, it is modifiable as shown by various
studies [4, 6–8]. An innovative form of outpatient contact
to improve self-efficacy is a protocolized Group Medical
Appointment (GMA), in which a protocolized Individual
Medical Appointment (IMA; care-as-usual) is incorporated
within a group consultation, in the presence of fellow pa-
tients and other medical professionals [9, 10] (Table 1).
We aim to analyze the effectiveness of GMA versus
IMA, in pediatric and adult patients with SCD, in a
study with a randomized controlled trial (RCT) design.
Hypotheses
We hypothesize that: 1) GMA will improve self-efficacy,
adherence, quality of life and the patient-professional rela-
tionship in SCD patients as compared to IMA; 2) and that
complementary periodic GMA’s (four in three years) will
be a cost-effective approach to intensify support for these
patients, since SCD requires time consuming support by
treating professionals.
Methods/Design
In this RCT with a parallel design, effects of protoco-
lized GMA versus protocolized IMA (care-as-usual)
will be tested in SCD patients, over a three year period,
for children and adults separately.
Participants
Although the natural course of the disease in our pa-
tient population differs according to disease severity, thepathophysiology of the disease, alarming signals, lifestyle
alterations and mode of inheritance do not differ. The
content of the GMA’s are applicable to our entire patient
population and therefore all patients with homozygous or
compound heterozygous SCD are eligible. We will exclude
patients with a first visit to the outpatient clinic, patients
who cannot communicate adequately due to language dif-
ficulties and/or hearing problems or patients who have be-
havioral problems which will limit group functioning (see
Fig. 1).
The expected study population will consist of: 40 chil-
dren and 60 adults with all types of SCD (HbSS, HbSC,
HbS beta + and 0 thalassemia) from the Sickle Cell Com-
prehensive Care Center in the Erasmus Medical Center -
Sophia Children’s Hospital Rotterdam, the Netherlands.
All patients/parents will be informed about the study
and will be asked to provide permission to use the data
for research purposes. Then they will be given one to two
weeks consideration time. When the patients/parents
agree to participate, written informed consent will be
asked by the investigator and the supervising physician.
Interventions
Care-as-usual: IMA
Protocolized care-as-usual consists of an IMA to the
(pediatric) hematology department at least every six
months with a total of seven IMA’s in a three year period.
Monitoring of organ dysfunction is performed by annual
laboratory analyses, echocardiography and transcranial
Doppler and duplex analysis (1–2 times a year), the latter
only in children. Consultation visits are also made to
various subspecialists, according to protocol (cardiologist,
clinical neurophysiologist, ophthalmologist) and when cli-
nically indicated (pulmonologist, gynecologist, neurologist,
nephrologist, anesthesiologist, orthopedic surgeon). All
patients included in the study will receive a personal dos-
sier in which sickle cell crises, emergency department
visits, hospital admissions and blood transfusions are
documented. This is of importance as many patients are
concomitantly monitored by physicians at other non-
academic hospitals. Furthermore, all patients or parents in
our comprehensive care center standardly receive extra
reminder letters and are contacted prior to appointments
by telephone to keep lost to follow-up to a minimum.
Intervention: GMA
In the intervention group, every other outpatient clinic
visit will be replaced by a protocolized GMA. GMA was
introduced by Noffsinger and Scott and recently pro-
moted by “Kwaliteitsinstituut voor de Gezondheidszorg
(CBO)” in the Netherlands, as an effective option to
optimize self- efficacy, adherence, as well as treatment
regimen and lifestyle alterations in chronically ill patients
[9–16]. During a GMA, approximately eight patients and
Fig. 1 Flowchart
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(pediatric) hematologist, during a 1.5 h session. Since it is
important to safeguard the heterogeneity of the groups,
we will not invite the same patients (and parents) to each
GMA, although sometimes there may be overlap. The
protocolized standard of care for our patient population
consists of two hospital visits per year. Since GMA’s
have been shown to be effective for the motivated pa-
tient [12], we have chosen not to exceed the two visits
to the hospital. Therefore, during this three year RCT,
the protocolized GMA will be performed every other six
months, leading to a frequency of once a year, with a
total of four GMA’s and three IMA’s in a three year
period.
A chairman trained to supervise a GMA, hosts and fa-
cilitates the sessions. Patients consent to confidentiality
in each session. Although all components of an IMA are
incorporated, a GMA allows more time to discuss dis-
ease related topics and psycho-education. In addition,information and social support from fellow-patients can
greatly improve self-efficacy and quality of life [11, 14]
(Table 2). GMA is provided for children and their par-
ents (all ages until approximately 16 years of age) by the
pediatric team (a pediatric hematologist, a clinical gen-
eticist, a sickle cell nurse and a social worker) and for
teenagers (approximately 16 years and older and in tran-
sition to the adult hospital) and adults by the adult team
(a hematologist, a clinical geneticist, two sickle cell
nurses and a social worker). Economically, GMA ap-
pointments are billed as an IMA.
Previous evidence of GMA-effectiveness
Various studies in adults with other diseases such as dia-
betes, severe headaches, cardiovascular and urological
problems have shown that GMA may enhance patients’
and physician’s satisfaction, patients’ self-efficacy, quality
of life, and that it can reduce emergency visits and hos-
pital admissions [12, 14, 17–21]. Moreover, it has been
Table 1 Characteristics of the individual- and group medical
appointments
Group medical
appointment
Individual medical
appointment
Number of patients 6–8 1
Duration of
appointment
90 min total 15 min per professional
Severity of disease Various severities
of disease
One severity of disease
Professionals Treating physician,
nurse, clinical geneticist,
social worker
Treating physician,
nurse, clinical geneticist,
social worker
Clinical examination Behind a screen in
conference room or in
another room (before or
after the appointment)
In physician’s office
Privacy Confidentiality protected
by the group
Completely
Table 2 Structure of (pediatric) sickle cell disease group medical
appointment
1. Measurement of weight and height of all participants.
2. Introduction by the appointed chairman with special attention to
procedure, privacy and allotted time.
3. Individual interview by treating physician specifically focusing on
individual disease symptoms and complications.
4. During the GMA disease-related topics are discussed, in accordance
to patient questions or introduced by the chairman:
Disease and therapy
Early identification of sickle cell crises and crises provoking factors
Interventions to influence sickle cell crises provoking factors.
Pain treatment regimens, importance of treating pain early and
adequately
Consequences of functional asplenia and importance of anticipating
possible consequences (antibiotic prophylaxis, vaccinations, early
treatment with broad spectrum antibiotics in case of fever)
Recognition of important or alarming disease symptoms: aggravation
of anemia, splenic sequestration, severe sickle cell crises needing
hospital attention, infections and respiratory problems, gallstones,
symptoms suggestive of cerebral infarctions, cognitive deterioration,
priapismus, bone infarctions
Education with regard to pathophysiological effects of treatment
options (hydroxycarbamide, chronic blood transfusions)
Importance of healthy lifestyle (enough rest, healthy diet,
consciousness of limitations)
Importance of informing school and others of disease
Regular dental consultations and importance of vaccinations
according to national guidelines
Lifestyle
Avoidance and early treatment of sickle cell crisis provoking factors
(cold, fever/infection, pain, high altitude, dehydration/enough fluids,
fatigue and stressful situations) and underlining specific social and
physical circumstances with risks: swimming lessons, alcohol,
menstrual period, intensive sporting activities
Encouragement of individual self-empowerment, self-efficacy
Frequent contact with Sickle Cell Comprehensive Care Center is
encouraged
Support and guidance with regard to job and career choice
Genetics
Explanation of different sickle cell genotypes
Inheritance of the disease and importance of genetic counseling
Explanation of meaning of coinheritance of alpha thalassemia and
persistent fetal hemoglobin levels (HbF)
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ing extensive patient education to modify disease course
and to prevent complications [14, 20, 21].
Innovative character
To date, GMA has not been applied in SCD and few have
been performed in pediatric populations [22]. We also
aim to quantify cost-effectiveness of the intervention, in
this time consuming disease, by an economic analysis.
Outcomes
Primary and secondary endpoints will be measured at base-
line (start of the study), after 1.5 years (after two GMA
visits) and after 3 years (after four GMA visits), in both
groups. Assessments are performed at the hospital, directly
before the outpatient visit and in presence of a psychologist.
Primary endpoint:
1. Self-efficacy as measured by the validated Sickle Cell
Self- Efficacy Scale [7];
Secondary endpoints:
2. Adherence to prescribed treatment by (pediatric)
hematologist, defined by:Options with regard to prenatal diagnosis and preimplantation
genetic diagnosis
5. At the end of the GMA diagnostic vena punctures and more private
individual consultations are performed and, if necessary, physical
examinations– Self-report (Morisky Medication Adherence
Scale) [23];
– Variations in adherence (Medication Adherence
Report Scale) [24];
– Blood values suggesting adherence to prescribed
medication (folic acid, hydroxycarbamide, iron
chelation therapy) such as: folic acid (nmol/l),
MCV (fl), fetal hemoglobin percentage (HbF %),
ferritine (mcg/l);
– Attendance at outpatient clinic visits or imaging
examinations (% of total planned).3. Quality of life as measured with the validated
Pediatric Quality of Life Inventory for children [25]
and SF-36 for adults [26].
4. Emergency visits and hospital admissions for SCD
related symptoms and complications. At t = 0,
Madderom et al. BMC Hematology  (2016) 16:21 Page 5 of 6morbidity of preceding 3 years will be measured as
baseline. All patients in the study will receive a
dossier in which sickle cell crises, emergency
department visits, hospital admissions, blood
transfusions will be documented.
5. Satisfaction with treating physician and nurse (by
visual analogue scale: score 1–10) [27, 28].
6. Measurement of costs and effects in the GMA and
IMA group by an economic analysis according to
Dutch guidelines and with respect to an increase in
self- efficacy.
Cost-effectiveness analysis
GMA’s will be compared with IMA’s in accordance with
Dutch guidelines [29]. Cost-effectiveness of GMA in SCD
will be assessed by calculating the incremental cost-
effectiveness ratio (ICER), defined as the difference in
costs of GMA compared to care-as-usual (IMA), divided
by the average change in effectiveness, with self-efficacy
measured with the validated Sickle Cell Efficacy Scale as
the primary outcome measure. An economic evaluation
will be performed from a healthcare perspective for the
period of three years after the start of the intervention.
For the calculation of the costs from a healthcare per-
spective, total medical care costs will be measured (e.g.
GMA, inpatient days, professional health caregivers’ ac-
tivities, medical procedures). Actual medical costs will
be calculated by multiplying the volumes of healthcare
use with the corresponding unit prices. Data on re-
source use will be collected from medical files. The cost
price of GMA will be determined with the bottom-up
micro-costing method [30], which is based on a detailed
assessment of all resources used. Therefore, costs for
all separate actions and time used by all individual
healthcare professionals will be measured. For the cal-
culation of other medical costs, we will use charges
as published in Dutch guidelines as a proxy of real
costs. We will perform a sensitivity analysis to assess
the stability of the results to changes in costs and ef-
fectiveness parameters [29].
Budget impact analysis
A Budget Impact Analysis (BIA) will be performed in ac-
cordance to principles for good BIA practice. A valid
framework will be provided according to Markov, lead-
ing to insight in budget consequences of desensitization,
by a range of predictions based on realistic estimates
and scenarios of input parameter values [31]. The likely
impact of GMA on center level and also on national
health plan budgets.
Sample size
As the effect size (which varies between Cohen’s d = 0.00
and d = 0.95) could only be estimated and is bestcomparable to that shown for cognitive behavioral ther-
apy [32], we presume effect of GMA on endpoints is
0.50 (moderate effect size according to Cohen) [33].
With a power of 0.80 and an alpha of 0.05 (two-tailed), a
sample size of 100 patients will suffice (two data sets;
children: 40 patients, with 20 in each arm; adults: 60 pa-
tients, with 30 in each arm). To adjust for loss to follow
up 65 adults and 45 children will be included.
Randomization
After informed consent, patients (children and adults
separately) will be randomized by the investigator with
the use of the Trial Online Process registration and
randomization program. Allocation will be known to all
involved in the study. The randomization process will
stratify by severity of disease (with severe SCD defined
as: HbSS or HbSβ0 and milder disease defined as: other
compound heterozygous forms of SCD). In order to in-
vestigate whether the study population is a representa-
tive sample of the total population in our hospital we
will compare background variables (age, gender, socio-
economic status and diagnosis) between both popula-
tions when the study is completed.
Discussion
This article presents the rationale and design of a RCT to
test the effectiveness of GMA versus IMA on self-efficacy,
adherence, quality of life and patient-professional relation-
ship in pediatric and adult patients with SCD. Further-
more, effects of GMA on medical costs (e.g., morbidity,
hospital admissions) will be tested. This is the first study
to investigate the effects of GMA on these parameters in
patients with SCD and is the first to evaluate the cost-
effectiveness of such an intervention. If the GMA’s prove
successful in improving self-efficacy, adherence and cost-
effectiveness, this innovation in SCD care may be dissemi-
nated at an (inter)national level.
Trial status
The trial opened to recruitment in January 2013 for the
children and in September 2015 for the adults and is still
ongoing.
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